Holger Thurm

4.7k total citations · 2 hit papers
48 papers, 2.2k citations indexed

About

Holger Thurm is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Holger Thurm has authored 48 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Holger Thurm's work include Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (10 papers). Holger Thurm is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (10 papers). Holger Thurm collaborates with scholars based in United States, Italy and Australia. Holger Thurm's co-authors include Todd M. Bauer, Alice T. Shaw, Benjamin Solomon, Gerson Peltz, Enriqueta Felip, Tony Mok, Anna Polli, Geoffrey Liu, Anna Maria Calella and Julien Mazières and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Holger Thurm

46 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Holger Thurm United States	19	1.7k	1.4k	624	470	242	48	2.2k
Giancarlo Bisagni Italy	25	832 0.5×	1.9k 1.4×	570 0.9×	747 1.6×	267 1.1×	127	2.9k
Shyhmin Huang United States	23	1.0k 0.6×	1.5k 1.0×	1.1k 1.7×	291 0.6×	147 0.6×	39	2.4k
S. Phan United States	15	1.4k 0.8×	1.6k 1.1×	495 0.8×	525 1.1×	547 2.3×	43	2.5k
Kimio Yonesaka Japan	25	1.2k 0.7×	2.2k 1.5×	789 1.3×	265 0.6×	125 0.5×	74	2.8k
Garry Schwartz United States	24	725 0.4×	1.1k 0.7×	760 1.2×	323 0.7×	336 1.4×	40	2.0k
Luigi Formisano Italy	25	772 0.5×	1.1k 0.8×	1.1k 1.8×	494 1.1×	236 1.0×	73	2.2k
Ben O’Leary United Kingdom	14	1.7k 1.0×	1.7k 1.2×	810 1.3×	1.3k 2.8×	341 1.4×	37	2.7k
Radek Lakomý Czechia	22	806 0.5×	1.3k 0.9×	1.2k 1.9×	1.0k 2.2×	296 1.2×	87	2.8k
Katherine E. Hutchinson United States	19	536 0.3×	920 0.6×	972 1.6×	595 1.3×	180 0.7×	48	1.8k
Jin‐Hee Ahn South Korea	25	821 0.5×	938 0.7×	549 0.9×	484 1.0×	122 0.5×	115	1.9k

Countries citing papers authored by Holger Thurm

Since Specialization

Citations

This map shows the geographic impact of Holger Thurm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Thurm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Thurm more than expected).

Fields of papers citing papers by Holger Thurm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Thurm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Thurm. The network helps show where Holger Thurm may publish in the future.

Co-authorship network of co-authors of Holger Thurm

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Thurm. A scholar is included among the top collaborators of Holger Thurm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Thurm. Holger Thurm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Geoffrey, Benjamin Solomon, Julien Mazières, et al.. (2025). Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. The Oncologist. 30(10).

Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2023). Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. Journal of Thoracic Oncology. 18(11). 1581–1593. 26 indexed citations

Chen, Joseph, Alessandra Bearz, Dong‐Wan Kim, et al.. (2023). Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Pharmacokinetics. 63(2). 171–182. 3 indexed citations

Bearz, Alessandra, Enriqueta Felip, Julien Mazières, et al.. (2022). 979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study. Annals of Oncology. 33. S998–S999. 5 indexed citations

Mazières, Julien, Laura Iadeluca, Alice T. Shaw, et al.. (2022). Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer. 174. 146–156. 23 indexed citations

Adkins, Douglas R., Assuntina G. Sacco, Jessica Ley, et al.. (2021). Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Oral Oncology. 115. 105192–105192. 27 indexed citations

Felip, Enriqueta, Alice T. Shaw, Alessandra Bearz, et al.. (2021). Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Annals of Oncology. 32(5). 620–630. 68 indexed citations

Solomon, Benjamin, Tony Mok, Hidetoshi Hayashi, et al.. (2021). 1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S957–S958. 2 indexed citations

Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2021). Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations. Cancer Research. 81(13_Supplement). LB043–LB043. 2 indexed citations

10.

Mazières, Julien, Laura Iadeluca, Alice T. Shaw, et al.. (2021). MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC. Journal of Thoracic Oncology. 16(3). S175–S176. 2 indexed citations

11.

Shaw, Alice T., Todd M. Bauer, Filippo de Marinis, et al.. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer. New England Journal of Medicine. 383(21). 2018–2029. 649 indexed citations breakdown →

12.

Ou, Sai‐Hong Ignatius, Benjamin Solomon, Alice T. Shaw, et al.. (2020). 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression. Annals of Oncology. 31. S842–S842. 1 indexed citations

13.

Cohen, Ezra E.W., Robert L. Ferris, Amanda Psyrri, et al.. (2020). 910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Annals of Oncology. 31. S658–S658. 30 indexed citations

14.

Shaw, Alice T., Benjamin Solomon, Rita Chiari, et al.. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 20(12). 1691–1701. 248 indexed citations

15.

Shaw, Alice T., Jean‐François Martini, Benjamin Besse, et al.. (2019). Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 9019–9019. 14 indexed citations

16.

Bauer, Todd M., Alice T. Shaw, Melissa L. Johnson, et al.. (2018). MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study. Journal of Thoracic Oncology. 13(10). S382–S383. 4 indexed citations

17.

Besse, Benjamin, Benjamin Solomon, Enriqueta Felip, et al.. (2018). Lorlatinib in patients (Pts) with previously treated ALK⁺ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.. Journal of Clinical Oncology. 36(15_suppl). 9032–9032. 12 indexed citations

18.

Spigel, David R., Martin J. Edelman, Tony Mok, et al.. (2012). Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(6). 500–504. 74 indexed citations

19.

Nabavi, Arya, Holger Thurm, Basilios Zountsas, et al.. (2009). FIVE-AMINOLEVULINIC ACID FOR FLUORESCENCE-GUIDED RESECTION OF RECURRENT MALIGNANT GLIOMAS. Neurosurgery. 65(6). 1070–1077. 153 indexed citations

20.

Thurm, Holger, Sebastian Ebel, Christina Kentenich, et al.. (2003). Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.. PubMed. 9(7). 2598–604. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact